Skip to main content
TipRanks
Go Ultimate75% OFF

Stille AB (STIL) AI Stock Analysis

0 Followers
SE:STIL

Stille AB

(Nasdaq OMX AB:STIL)

Select Model
Rating:83Outperform
Price Target:SEK 292.00â–²(9.98% Upside)
Action:reiterated
Date:10/27/26

Stille AB earns a strong overall score, primarily driven by its stellar financial execution, debt-free balance sheet, and record-breaking Q3 sales. Long-term technical trends remain firmly bullish, and its P/E ratio is well-justified by the impressive organic growth and continued margin expansion.

Positive Factors
Revenue and Profitability GrowthStrong organic growth is being accompanied by faster EBITDA expansion, indicating operating leverage rather than growth purchased solely through higher costs. If sustained, this combination can strengthen earnings power, fund commercial investment, and support continued competitive progress over the next several quarters.
Negative Factors
Backorders and Supply NormalizationPersistently elevated backorders can delay customer deliveries, defer revenue recognition, and constrain the company's ability to convert strong underlying demand into repeatable sales. Continued investment may improve service, but normalization remains necessary for execution and customer experience.

Stille AB (STIL) vs. iShares MSCI Sweden ETF (EWD)

-20%0%20%40%60%SE:STIL+50.00%EWD+15.64%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
SEK 2.39B
Dividend Yield
―
Average Volume (3M)
9,556
Price to Earnings (P/E)
24.8
Beta (1Y)
0.28
Revenue Growth
28.75%
EPS Growth
138.25%
Country
Sweden
Employees
239
Sector
General
Sector Strength
55
Industry
Medical - Instruments & Supplies

Stille AB Business Overview & Revenue Model

Company Description

Stille AB develops, manufactures, and distributes medtech products in Sweden and internationally. It operates through the Surgical Instruments and Surgical Tables segments. The Surgical Instruments segment offers surgical scissors, including SuperCut...

How the Company Makes Money

Stille makes money primarily by selling medical technology products to healthcare providers and related procurement channels. Key revenue streams include: (1) Sales of surgical instruments: revenue generated from manufacturing and supplying reusable...

Stille AB Earnings Call Summary

Earnings Call Date:Oct 23, 2026(Q3-2026)|% Change Since:-0.93%|Next Earnings Date:Feb 12, 2027
Earnings Call SentimentPositive

The call was strongly positive, with record rolling 12-month sales, robust organic growth, improved margins, sharply higher operating cash flow, stronger delivery performance, and a net cash position. The main challenges were elevated backorders, currency-related pressure on Surgical Instruments margins, partially outstanding tariff refunds, and management's caution that the exceptional 30% Surgical Tables growth rate is not expected to continue at the same level.

Positive Updates

Strong Q3 Revenue Growth
Q3 revenue increased to SEK 170.6 million, up 22.9% year over year, with organic growth of 16.5%. Currency translation contributed SEK 2.1 million, resulting in total growth of 21.5% and organic growth of 15.2% in constant currencies.

Negative Updates

Backorders Remain Elevated
Although backorder levels were reduced during Q3 and further reduction is expected in Q4, management stated that elevated backorder levels remain and that the supply situation is not fully back to normal.

Company Guidance

Management reiterated its long-term guidance to deliver +10% organic growth, an EBITDA margin of 25% and leverage of less than 3x net debt/EBITDA; it expects a gradual decrease in backorder level and a further reduction during Q4. Management said instrument-market growth is more a mid-single-digit growth and that +10% organic growth is a realistic target, while table sales growth of around 30% versus 2025 is clearly not a growth you should just extrapolate going into 2027 and 30% next year might be a stretch; no specific outlooks on individual segments, nor year by year outlook, were provided. Management’s target is to recover more tariff refunds, with the SEK 5.2 million received estimated at around 60% of what it would expect to see.

Stille AB Financial Statement Overview

Summary

Outstanding financial health characterized by a flawless 0.0 debt-to-equity ratio, expanding profit margins, and robust revenue and free cash flow generation.

Income Statement

88Very Positive

Balance Sheet

95Very Positive

Cash Flow

84Very Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue711.42M567.63M569.95M294.89M246.35M187.09M
Gross Profit352.93M287.97M295.64M132.17M111.57M83.46M
EBITDA143.34M109.01M129.50M56.04M44.78M28.89M
Net Income96.27M55.70M58.21M26.65M27.32M16.10M
Balance Sheet
Total Assets1.17B1.05B1.00B804.89M342.55M308.85M
Cash, Cash Equivalents and Short-Term Investments170.71M118.66M158.49M241.45M36.68M27.80M
Total Debt0123.26M63.09M62.94M70.77M81.48M
Total Liabilities360.44M345.54M301.70M172.64M152.74M160.75M
Stockholders Equity809.76M708.71M699.40M632.25M189.81M148.10M
Cash Flow
Free Cash Flow64.22M15.46M59.24M24.37M23.89M-11.74M
Operating Cash Flow87.80M36.05M73.53M37.28M31.94M7.28M
Investing Cash Flow-33.88M-104.30M-330.31M-12.90M-8.04M-51.90M
Financing Cash Flow-25.45M36.16M171.40M178.99M-18.54M33.22M

Stille AB Technical Analysis

Technical Analysis SentimentPositive
Last Price265.50

Price Trends

50DMA249.42Positive
100DMA245.29Positive
200DMA232.07Positive

Market Momentum

MACD2.43Negative
RSI62.44Neutral
STOCH79.82Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:STIL, the sentiment is Positive. The current price of 265.50 is above the 20-day moving average (MA) of 255.13, above the 50-day MA of 249.42, and above the 200-day MA of 232.07, indicating a bullish trend. The MACD of 2.43 indicates Negative momentum. The RSI at 62.44 is Neutral, neither overbought nor oversold. The STOCH value of 79.82 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:STIL.

Stille AB Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

SE:STIL against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SE:STILSE:STIL83OutperformSEK 2.39B24.77――28.75%138.25%
SE:BONEXSE:BONEX81OutperformSEK 21.15B77.7729.00%―25.20%79.34%
SE:ALIF.BSE:ALIF.B74OutperformSEK 22.21B34.6211.32%0.82%1.62%63.45%
SE:SUSSE:SUS73OutperformSEK 2.88B26.88――4.52%53.01%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
SE:FLUOSE:FLUO45NeutralSEK 479.03M-6.57―――-23.57%
SE:OSSDSE:OSSD45NeutralSEK 387.19M-7.74――-11.89%-11.85%

* General Sector Average

Performance Comparison

-50%0%50%SE:STILSE:ALIF.BSE:BONEXSE:SUSSE:OSSDSE:FLUODec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SE:STIL and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SE:STILStille AB265.5095.0055.72%
SE:ALIF.BAddLife AB Class B182.103.652.05%
SE:BONEXBONESUPPORT HOLDING AB321.20119.2059.01%
SE:SUSSurgical Science Sweden AB56.45-16.10-22.19%
SE:OSSDOssDsign AB3.50-7.48-68.12%
SE:FLUOFluoGuide A/S29.30-10.70-26.75%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 27, 2026